The Lancet published peer-reviewed results from a Phase 3 efficacy trial of the R21/Matrix-M™ malaria vaccine. The World Health Organization recently prequalified the vaccine, leading to a global rollout expected to begin in mid-2024. With data from the trial, the vaccine’s effectiveness was reported as 75% in areas with seasonal malaria transmission and 68% in regions with perennial malaria. The most common side effects were fever and injection site pain. Developed by the University of Oxford and Serum Institute of India, the vaccine contains Novavax’s Matrix-M™ adjuvant. Regulators in Ghana, Nigeria, and Burkina Faso have also licensed the vaccine. Malaria poses a significant threat globally, particularly in Africa, and with this vaccine, its impact may be reduced.
Source link
Phase 3 trial of new malaria vaccine reveals promising results in protecting children
